This week we participated in the Lennox-Gastaut Syndrome (LGS) Foundation 9th International Family & Professional Conference in Arizona! Our team appreciated spending time with the inspiring individuals living with LGS and their loved ones. Thank you to LGSF and the community for allowing us to be involved in this important event!
Longboard Pharmaceuticals
Biotechnology Research
La Jolla, CA 8,454 followers
We Are Committed To Transforming the Lives of Patients With Neurological and Rare Diseases.
About us
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard plans to advance bexicaserin (LP352), an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with no observed impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. Longboard recently reported positive topline data from a Phase 1b/2a clinical trial (the PACIFIC Study) evaluating bexicaserin in participants ages 12 to 65 years old with Developmental and Epileptic Encephalopathies (DEEs), including Lennox-Gastaut syndrome, Dravet syndrome and other DEEs. Longboard is also evaluating LP659, an oral, centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, which is in development for the potential treatment of rare neuroinflammatory conditions.
- Website
-
http://www.longboardpharma.com/
External link for Longboard Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- La Jolla, CA
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
Get directions
4275 Executive Square
Suite 950
La Jolla, CA 92037, US
Employees at Longboard Pharmaceuticals
Updates
-
Today, we announced that the U.S. FDA has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older. We are so happy to share this tremendous milestone and excited for the potential implications for the DEE community! https://bit.ly/3XLGnQX
-
-
We’re proud to stand with the Dravet syndrome community, especially today for International Dravet Syndrome Awareness Day. This weekend we met with families at the Dravet Syndrome Foundation Biennial Family & Professional Conference, and had the opportunity to learn more about the joys and hardships families and their Dravet warriors face living with this Developmental and Epileptic Encephalopathy. It was an honor to present and participate at this conference, and to interact with everyone there!
-
-
Thank you to Life Science Cares San Diego and our Longboard team members that volunteered at Feeding San Diego last week. Great teamwork for a great cause!
-
-
Today, we raise awareness for CDKL5 Deficiency Disorder, a rare genetic condition causing developmental and epileptic encephalopathy and early-onset seizures. Last week our team had the privilege of spending time with this amazing community at the International Foundation for CDKL5 Research (IFCR) 6th Annual Conference, where families, clinicians, industry and researchers came together to celebrate success and work towards an even better future for individuals living with #CDKL5. #CDKL5Awareness #CDKL5Forward
-
-
Today, we announced positive interim results from our ongoing 52-week open-label extension (OLE) of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies (DEEs). Additional detail can be found in our press release https://bit.ly/4efEgKU & OLE presentation https://bit.ly/3OEgIEd.
-
-
Great week in Boston at the The Association of Bioscience Financial Officers International 2024 Conference! Brandi Roberts, Longboard's CFO, participated in the CFO Best Practices panel. #ABFO #ABFO2024
-
-
If you are attending #BIO2024 we invite you to attend a panel featuring Steven Spector, Longboard’s EVP, Head of Business Development and General Counsel, and other esteemed speakers, for a discussion regarding the biotech IPO landscape. https://bit.ly/4aDagW7
-
-
We look forward to attending #BIO2024 in our hometown of San Diego next week! If you are interested in meeting with our team, please contact us at Info@longboardpharma.com.
-
-
Longboard Pharmaceuticals reposted this
Thank you Longboard Pharmaceuticals for standing with the global TSC community this #tscglobalawarenessday!